Bristol-myers Squibb Compnay

Genomic Health, Inc.

David J Mauro

Joffre B Baker

Steven Shak

Drew Watson

Tara Maddala

Shirin K Ford

The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.

Growing community of inventors

Redwood City, CA, United States of America

David J Mauro